Journal of Clinical Oncology
Articles in this Issue
SWOG/NRG S1914: Randomized phase III trial of induction/consolidation atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC.
8003 Background: Stereotactic body radiation therapy (SBRT) is the standard of care (SoC) for early stage, medically inoperable non-small cell lung cancer...
Analysis of trends and disparities in laryngeal cancer mortality from 1999 to 2020.
e18136 Background: Laryngeal cancer (LC) comprises one-third of all head and neck cancers, presenting substantial morbidity and mortality risks. Despite t...
A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC).
TPS5627 Background: Ovarian cancer (OC) is the fifth leading cause of cancer-related death among women in the United States, with 12,730 estimated deaths...
Systematic screening of perception of curability among patients with advanced cancer: A longitudinal analysis.
12110 Background: Clinicians do not routinely assess patients’ illness understanding despite its importance in decision making. Systematic screening of il...
Investigating practice patterns in bone marrow biopsies for cutaneous T-cell lymphoma: A multicenter clinician survey.
e19075 Background: Bone marrow biopsy (BMB) is widely used to evaluate extracutaneous involvement in cutaneous T-cell lymphoma (CTCL), particularly in adv...
Demographic and regional trends in female genital neoplasm mortality in the United States from 1999 to 2020.
e13807 Background: Female malignant genital neoplasms (FMGNs), including cervical, ovarian, uterine, and vulvar cancers, collectively contribute significa...
Impact of neoadjuvant chemotherapy on survival outcome in advanced endometrial cancer in Hispanic vs non-Hispanic women.
e17649 Background: Neoadjuvant chemotherapy, while not the first line treatment for advanced stage endometrial carcinoma (ASEC), is often a good option fo...
Breast cancer in chronic lymphocytic leukemia patients: Characteristics and survival outcomes.
e13868 Background: Chronic lymphocytic leukemia (CLL) is associated with genetic mutations (e.g. TP53) and immune dysregulation, predisposing patients to...
Breast cancer care capacity in Côte d'Ivoire: Insights from a novel multidisciplinary provider survey.
e13863 Background: Breast cancer mortality is disproportionately high in low-middle income countries (LMICs), but few tools exist to measure comprehensive...
Novel protein biomarkers for early detection of pancreatic ductal adenocarcinoma using longitudinal serum protein measurements and machine learning.
e14536 Background: Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive with one- and five-year average net survival rates of approximately 28% an...
Survival in ER-positive/HER2-negative non-metastatic invasive breast cancer.
e12631 Background: Non-metastatic invasive breast cancer, estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-),...
Cardiotoxicity in early breast cancer: Risk factors and predictors.
e12633 Background: Breast cancer ranks second in incidence and fourth in mortality globally (GLOBOCAN 2022). Effective antineoplastic treatments have incr...
Temporal trends in the incidence of multiple myeloma in the Middle East and North Africa over the past three decades.
e19568 Background: Multiple myeloma (MM) is a common hematologic malignancy in aging populations, representing 10% of global hematologic cancers, with hig...
Phase 2 peri-operative study of fianlimab + cemiplimab + chemotherapy versus cemiplimab + chemotherapy in resectable early-stage non-small cell lung cancer (NSCLC).
TPS8117 Background: Co-blockade of lymphocyte activation gene 3 (LAG-3) and programmed cell death-1 (PD-1) may enhance the efficacy of anti–PD-1 therapies...
Preliminary results of ZG005, a bispecific antibody targeting PD-1 and TIGIT, as monotherapy in patients with advanced cervical cancer.
5528 Background: ZG005, a PD-1 and TIGIT dual-specific antibody, is a promising immunotherapy for tumors. By blocking both pathways, it can synergisticall...
<i>NTRK1-3</i> point mutations in non-small cell lung cancer: Molecular profiling.
e20541 Background: Neurotrophic receptor tyrosine kinase (NTRK) fusions occur in less than 1% in non-small cell lung cancer (NSCLC) cases and have been th...
NeoACTIVATE arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable stage III melanoma.
9503 Background: Neoadjuvant ± adjuvant immunotherapy improves event-free survival relative to adjuvant immunotherapy alone for patients with high-risk re...
Biomarkers of neoadjuvant dalpiciclib in patients with operable HER2-negative luminal B breast cancer in the DANCER trial.
600 Background: DANCER (NCT05640778) was a circulating tumor DNA (ctDNA)-directed, single-arm, phase II trial investigating the clinical activity of dalpi...
A single-institution retrospective study of multicentric gliomas stratified by <i>IDH</i> mutational status.
2078 Background: Multicentric glioma (MCG) is a subset of diffuse glioma that can be synchronous or metachronous and is defined as the occurrence of two o...
Prevalence of claudin 18.2 (CLD18.2) in gastric cancers and clinical correlation.
e16025 Background: There is no data from India about the prevalence of CLD18.2 in patients with gastric adenocarcinomas (GC). Methods:...
Effect of treatment resistance on CSPG4+ expression in metastatic melanoma across multiple treatment lines.
e21540 Background: Immune checkpoint inhibitors (ICIs) and targeted therapies have improved outcomes in metastatic melanoma, but resistance remains a majo...
Inpatient burden of chimeric antigen receptor T-cell therapy: A National Inpatient Sample study.
e23351 Background: Chimeric Antigen Receptor T-Cell (CAR-T) Therapy has emerged as the groundbreaking therapy for hematologic malignancies. Despites its e...
Employer-sponsored insurance, paid sick leave, and financial toxicity among cancer survivors.
11107 Background: Financial toxicity (FT), the adverse economic effects resulting from cancer, its treatment, and associated long-term effects, may affect...
Assessment of clinical utility and microsatellite instability detection on the Marsden360 ctDNA sequencing panel.
e15058 Background: This project aimed to verify the Marsden360 circulating tumour DNA (ctDNA) sequencing panel for detecting microsatellite instability (M...
The impact of prior neoadjuvant/adjuvant chemotherapy (NACT/ACT) on fruquintinib plus sintilimab outcomes in advanced endometrial cancer (EMC) patients with pMMR status: A subgroup analysis of FRUSICA-1.
5611 Background: FRUSICA-1 (NCT03903705) was an open-label, single-arm, pivotal phase 2 study to evaluate the efficacy and safety of fruquintinib (F, a hi...